Literature DB >> 1985484

Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy.

H Lewis1, T M Aaberg.   

Abstract

During the last two years, we performed vitreoretinal surgery on 37 eyes with retinal detachments and recurrent severe proliferative vitreoretinopathy in 37 patients who had had previous failed scleral buckling and vitreous surgery for proliferative vitreoretinopathy. Anterior proliferative vitreoretinopathy was present in 32 of 37 eyes (86%); posterior proliferative vitreoretinopathy of fixed retinal folds in four quadrants of narrow or closed funnel shape occurred in 23 of 37 eyes (62%); and subretinal proliferation was noted in 16 of 37 eyes (43%). The retinas in 12 eyes (32%) redetached from new or recurrent anterior proliferative vitreoretinopathy in nine eyes, reopening of pre-existing retinal breaks in two eyes, or recurrent posterior periretinal proliferation in one eye. With additional vitreoretinal procedures in six eyes and after a mean follow-up period of 11 months, 27 of 37 retinas (73%) were totally reattached, and an additional five eyes (13%) had retinal reattachment posterior to the scleral buckle. Of the 32 patients with posterior retinal reattachment, final visual acuity of 5/200 or better was attained in 19 eyes (59%).

Entities:  

Mesh:

Year:  1991        PMID: 1985484     DOI: 10.1016/s0002-9394(14)76890-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  15 in total

1.  Primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment.

Authors:  C Batman; O Cekic
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

2.  Retrospective comparison of 25-gauge vitrectomy for repair of proliferative vitreoretinopathy with or without anterior proliferation.

Authors:  Tatsuhiko Sato; Kazuyuki Emi; Hajime Bando; Toshihide Ikeda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-07       Impact factor: 3.117

Review 3.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

4.  Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy.

Authors:  Sunil Ganekal; Syril Dorairaj
Journal:  Saudi J Ophthalmol       Date:  2014-03-21

5.  Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?

Authors:  R G Williams; S Chang; M R Comaratta; G Simoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

6.  Postvitrectomy hypotonia: the role of the vitreous and retinochoroidal lesions.

Authors:  H D Schubert; K Kuang; J Fischbarg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-06       Impact factor: 3.117

7.  Use of perfluorocarbon liquids in proliferative vitreoretinopathy: results and complications.

Authors:  U Stolba; S Binder; M Velikay; P Datlinger; A Wedrich
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

8.  Virtual retinectomy: indocyanine green-assisted internal limiting membrane peeling as a surgical adjunct in repair of recurrent rhegmatogenous retinal detachment due to PVR.

Authors:  John R Minarcik; Manfred A von Fricken
Journal:  Clin Ophthalmol       Date:  2012-04-27

9.  Vitreous incarceration in patients undergoing second 20-gauge pars plana vitrectomy for recurrent retinal detachment.

Authors:  Yongxin Zheng; Haotian Lin; Wen Liu; Dandan Wang; Suying Huang
Journal:  ISRN Ophthalmol       Date:  2011-10-09

10.  Anatomical and Functional Outcomes of Vitrectomy with/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment.

Authors:  Samir El Baha; Mahmoud Leila; Ahmed Amr; Mohamed M A Lolah
Journal:  J Ophthalmol       Date:  2021-07-20       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.